JP Morgan Chase
KRTX

JP Morgan Chase’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

JP Morgan Chase’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-30,552
Closed -$9.67M – 8036
2023
Q4 		$9.67M Sell
30,552
-3,675
-11% -$714K ﹤0.01% 2498
2023
Q3 		$5.79M Sell
34,227
-27,516
-45% -$5.17M ﹤0.01% 2721
2023
Q2 		$13.4M Buy
61,743
+9,086
+17% +$1.95M ﹤0.01% 2027
2023
Q1 		$9.56M Buy
52,657
+16,045
+44% +$3.07M ﹤0.01% 2321
2022
Q4 		$7.2M Buy
36,612
+3,315
+10% +$711K ﹤0.01% 2540
2022
Q3 		$7.49M Buy
33,297
+9,331
+39% +$1.89M ﹤0.01% 2395
2022
Q2 		$3.03M Buy
23,966
+3,748
+19% +$431K ﹤0.01% 3214
2022
Q1 		$2.56M Buy
20,218
+3,317
+20% +$373K ﹤0.01% 3559
2021
Q4 		$2.21M Buy
16,901
+1,388
+9% +$179K ﹤0.01% 3784
2021
Q3 		$1.9M Buy
15,513
+1,231
+9% +$142K ﹤0.01% 3838
2021
Q2 		$1.63M Buy
14,282
+4,181
+41% +$489K ﹤0.01% 3941
2021
Q1 		$1.21M Buy
10,101
+2,976
+42% +$337K ﹤0.01% 4090
2020
Q4 		$724K Buy
7,125
+1,236
+21% +$115K ﹤0.01% 4153
2020
Q3 		$465K Buy
5,889
+661
+13% +$56.3K ﹤0.01% 4018
2020
Q2 		$582K Buy
5,228
+1,841
+54% +$160K ﹤0.01% 3790
2020
Q1 		$244K Buy
3,387
+1,884
+125% +$161K ﹤0.01% 4187
2019
Q4 		$113K Sell
1,503
-506
-25% -$22.2K ﹤0.01% 4855
2019
Q3 		$32K Sell
2,009
-25,040
-93% -$487K ﹤0.01% 5308
2019
Q2 		$542K Buy
+27,049
New +$542K ﹤0.01% 4202

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

JP Morgan Chase's KRTX Position: Q1 2024 in Review

JP Morgan Chase sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 30,552 shares — an estimated $9.67M sold.

JP Morgan Chase first reported a position in KRTX in Q2 2019 and held it in 19 quarters. The position peaked at $13.4M in Q2 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • JP Morgan Chase reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • JP Morgan Chase sold 30,552 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $9.67M.
  • JP Morgan Chase first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 19 quarters.
  • JP Morgan Chase's Karuna Therapeutics, Inc. Common Stock position peaked at $13.4M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.